Navigation Links
Spectral announces second quarter 2009 results
Date:8/13/2009

TORONTO, Aug. 13 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc., (TSX: SDI), a company focused on bringing to market a diagnostic and a therapeutic targeting severe sepsis, today announced its financial results for the second quarter ended June 30, 2009.

"During the quarter, results of the EUPHAS trial in Italy were published in the Journal of American Medical Association (JAMA). The findings showed that the Toraymyxin(TM) cartridge significantly reduced mortality from sepsis in a prospective controlled trial, further supporting our planned U.S. registration trial for this product," said Dr. Paul Walker, President and CEO of Spectral. "The degree of reduction in mortality demonstrated by Toraymyxin(TM) in the EUPHAS trial is an unprecedented result for sepsis therapies. We believe that Toraymyxin(TM), when used together with our proprietary Endotoxin Activity Assay (EAA(TM)), has the potential to fulfill an unmet need for the approximately 125,000 patients that develop severe sepsis or septic shock in the U.S. each year. Our work towards obtaining an Investigational Device Exemption (IDE) from the U.S. FDA is on schedule and we should be in a position to initiate our registration trial for Toraymyxin(TM) following IDE approval."

Financial Review

For the second quarter ended June 30, 2009, Spectral reported revenues of $776,000, compared to $785,000 for the corresponding period in 2008. For the six months ended June 30, 2009, revenues were $1,618,000 compared to $1,449,000 for the same 2008 period. Sales of the EAA(TM) diagnostic increased, while royalty and reagent revenues from the Company's proprietary Troponin I products remained consistent with prior year levels.

Operating expenses for the second quarter ended June 30, 2009 were $1,186,000, compared to $978,000 for the corresponding period in 2008. For the six months ended June 30, 2009, operating expenses were $2,229,000 compared to $1,954,000 in the
'/>"/>

SOURCE Spectral Diagnostics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
2. US Patent and Trademark Office Allows CRis Patent Application for Spectral Imaging of Deep Tissue
3. CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy
4. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
5. Spectral appoints Anthony Bihl to Board of Directors
6. Spectral announces 2007 financial results
7. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
8. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
9. Spectral and Toray expand collaboration to include new geographic territories
10. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
11. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Vermillion, Inc. (Nasdaq:   VRML), a ... today that investors including Oracle Investment Management, ... several Vermillion directors have agreed to purchase approximately ... stock and warrants to purchase unregistered shares of ... Under the terms of the private ...
(Date:12/22/2014)... Malvern, PA & Brussels (PRWEB) December 22, 2014 ... Education (CfPIE), the global leader of technical training ... Society for Clinical Data Management (SCDM) to ... training and certification programs —providing access to the ... The partnership extends SCDM members with 10% off when ...
(Date:12/22/2014)... MISSION VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... announce that CoPatient, an online medical bill review and ... newest offering in the FREE WellCard Savings discount health ... a medical bill that was more than they expected ... help members reduce health care costs, WellCard Savings is ...
(Date:12/19/2014)... 19, 2014 Charm Sciences is pleased ... the Detection of Aflatoxin M1 in raw commingled milk ... third party validation. The peer reviewed report of the ... Institute for Agricultural and Fisheries Research (ILVO-T&V) has been ... Aflatoxin B1, the most toxic aflatoxin and a known ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... Complex(TM) Targets the ... Aging, EL SEGUNDO, Calif., Sept. 24 With ... AHA,s, and the,category of Internal Skincare(R), now Dr. Howard ... Murad Inc. and author of,Wrinkle-Free Forever and The Cellulite ...
... Expands Life Sciences Company,s Leadership Team, INDIANAPOLIS, ... leader in short-term and long-term biomaterials storage,sample management ... a,local life sciences leader, joins the company as ... this newly created position, Ball is responsible for ...
... Memory and Cognition Validate Clinical ... ... AMRN ) ("Amarin" or "Company") announced that the results ... (EPA) have been published in the "Journal of,Neurochemistry" (Minogue AM ...
Cached Biology Technology:Murad Boosts Skin Immunity With the New Murad(R) Professional Line 2BioStorage Technologies Appoints Lori Ball as Vice President 2BioStorage Technologies Appoints Lori Ball as Vice President 3Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 2Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 3Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 4Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 5
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... estrogen receptors are more difficult to treat than ... Meeting 2013 demonstrates an investigational drug, Paragazole, that ... and that increases the sensitivity of these cells ... do is use triple-negative breast cancer models to ...
... identified four genes newly associated with severe childhood obesity. ... variations in severely obese children. The team found ... help to maintain protein receptors known to be involved ... targets for the development of new drugs against obesity. ...
... biologist at the Florida State University College of Medicine ... closer to understanding how life first emerged on Earth ... team produced data supporting the idea that 10 amino ... years ago were capable of forming foldable proteins in ...
Cached Biology News:Finding genes for childhood obesity 2Researcher offers clues on the origins of life 2Researcher offers clues on the origins of life 3
... Custom Synthesis Service provides you ... to knockdown any gene. We ... base pairs with terminal dT ... other lengths of your choice. ...
... is ideal for developing single and multi-analyte ... contains the new, improved, and user friendly ... can design specific templates for commercial or ... integrated graphing and data regression capabilities; the ...
Polyclonal Antibody to HADHB...
3T3 cells (RSV-transformed) Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: